(return to previous page)
Our myelin repair research program is the proof-of-concept project for our Accelerated Research Collaboration™ model (ARC™). The ARC model is a wholly integrated strategy that considers all elements of the basic research, drug discovery and drug development value chain.
Our work is guided by senior scientists and advisors from academia and the pharmaceutical industry. All research is overseen and managed by our staff of experienced industry professionals.
Many believe the ARC model has the potential to shorten the time to market for new medicines for all diseases. Proving the model’s effectiveness through our myelin repair research program is the first step in demonstrating the model’s effectiveness and replicability for other disease indications.
In preparation for seeking FDA approval for a myelin repair clinical trial, we established our Clinical Advisory Board led by Dr. Henry McFarland, Former Chief of the Neuroimmunology Branch and Director of Clinical Neuroscience at the National Institute for Neurological Disorders and Stroke at the National Institutes of Health. The Clinical Advisory Board is ensuring that the appropriate steps are taken to facilitate the development of effective trials. In 2011, we launched a biomarker development initiative to establish systematic, measurable endpoints for myelin repair. The availability of such biomarkers will help to accelerate the pace of clinical trials.
The success of our discovery biology program has provided us with a plethora of opportunities for further validation of the more than 100 myelin repair targets identified in our laboratories. At this time we have two development paths before us:
Designed to improve the odds of successful clinical trials, our translational medicine platform will ensure that to the extent possible there is consistent and concordant data in cell cultures, multiple animal models and assays, and in human tissue.
Our discovery biology program is a managed collaboration that brings together Principal Investigators with complementary knowledge in neurobiology, immunology, and myelin research. Their research is organized in a detailed research plan that addresses seven key areas that are believed to hold the answers to myelin repair. The graphic below shows each of the seven key areas and how the expertise of the funded laboratories crosses over from one area to another.
The plan is reviewed and revised annually by a Scientific Advisory Board of senior neuroscientists widely recognized as experts in their fields. The experimental design is informed by our Drug Discovery Advisory Board of experienced “drug hunters” who ensure the clinical relevance of the experiments and help set priorities for further development of the most promising therapeutic targets.
Our discovery biology program funds more than 35 full-time scientists in laboratories at Stanford University, Case Western Reserve University, the University of Chicago, Northwestern University, the University of California, San Francisco and the University of Melbourne and the National Institutes of Health.
Roll over to read more about each area of the research plan.